Have You Seen PRISMA?
Systematic reviews and meta-analyses are needed to synthesize evidence regarding clinical questions. Unfortunately the quality of these reviews varies greatly. As part of a movement to improve the transparency and reporting of important details in meta-analyses of randomized controlled trials (RCTs), the QUOROM (quality of reporting of meta-analysis) statement was developed in 1999. In 2009, that guidance was updated and expanded by a group of 29 review authors, methodologists, clinicians, medical editors, and consumers, and the name was changed to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Although some authors have used PRISMA to improve the reporting of systematic reviews, and thereby assisting critical appraisers assess the benefits and harms of a healthcare intervention, we (and others) continue to see systematic reviews that include RCTs at high-risk-of-bias in their analyses. Critical appraisers might want to be aware of the PRISMA statement.
1. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, et al. Improving the 8 quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354:1896-1900. PMID: 10584742.
2. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 Jul 21;339:b2700. doi: 10.1136/bmj.b2700. PubMed PMID: 19622552.